Successful Treatment with UVA 1 Laser of Non - Responder Vitiligo Patients

Authors

  • Torello Lotti University G. Marconi of Rome, Dermatology and Venereology, Rome
  • Georgi Tchernev Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia
  • Uwe Wollina Städtisches Klinikum Dresden, Department of Dermatology and Venereology, Dresden, Sachsen
  • Katlein França University of Miami School of Medicine, Miami, Florida
  • Jacopo Lotti University G. Marconi of Rome - Dept. of Nuclear, Subnuclear and Radiation Physics, Rome
  • Francesca Satolli Universita degli Studi di Parma Dipartimento di Medicina Clinica e Sperimentale, Department of Dermatology, University of Parma, Parma
  • Miriam Rovesti Universita degli Studi di Parma Dipartimento di Medicina Clinica e Sperimentale, Department of Dermatology, University of Parma, Parma
  • Serena Gianfaldoni University G. Marconi of Rome, Dermatology and Venereology, Rome

DOI:

https://doi.org/10.3889/oamjms.2018.047

Keywords:

Vitiligo, UVA1, Laser Alba 355®, Repigmentation, Safe profile

Abstract

The Authors discuss their experience in treating non-responder vitiligo patients with a UVA-1 laser. Laser Alba 355® is an innovative device of target UVA - 1 phototherapy. The present report suggests that UVA1 laser could be an applicable therapeutic option in patients with vitiligo, also for the ones who did not respond to the more conventional phototherapies.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Lee BW, Schwartz RA, Hercogová J, Valle Y, Lotti TM. Vitiligo road map. Dermatol Ther. 2012; 25(Suppl. 1):S44-56. https://doi.org/10.1111/dth.12006 PMid:23237038

Sun X, Xu A,Wei X, et al. Genetic epidemiology of vitiligo: a study of 815 probands and their families from south China. Int J Dermatol. 2006; 45 (10): 1176–1181. https://doi.org/10.1111/j.1365-4632.2006.02907.x PMid:17040433

Lotti T, Hautmann G, Hercogovà J. Vitiligo: disease or symptom?From the confusion of the past to current doubts. In: Lotti T, Hercogovà J, eds. Vitiligo. Problems and solutions. New York, NY, Basel: Marcel Dekker, Inc., 2004: 1-14. PMid:15063608

Shah AA, Sinha AA. Oxidative stress and autoimmune skin disease. Eur J Dermatol. 2013; 23(1):5-13. PMid:23420016

Lotti T, Hanna D, Buggiani G, Urple M. The color of the skin: psyco - anthropologic implications. J Cosmet Dermatol. 2005; 4(3):219-20. https://doi.org/10.1111/j.1473-2165.2005.00316.x PMid:17129270

Gianfaldoni S, Zarrab Z and Lotti T. Phototherapy and Vitiligo Re-pigmentation: From PUVA to Micro-focused Phototherapy. Journal of Pigmentary Disorders. 2014; 1:102.

Lotti TM, Hercogova J, D'Erme AM et Al. UVA -1 Light vs UVA -1 Laser emission Devices. In UVA1 in dermatology. Evidence, data, hypotheses. Nuova Prhomos Publishing House Italy, 2013: 68-71.

Tewari A, Grage MM, Harrison GI, et Al. UVA1 is skin deep: molecular and clinical implications. Photochem Photobiol Sci. 2013; 12(1):95-103. https://doi.org/10.1039/C2PP25323B PMid:23192740

Lotti TM, Hercogova J, D'Erme AM et Al. UVA-1 in dermatology: clinical studies and observations. In UVA1 in dermatology. Evidence, data, hypotheses. Nuova Prhomos Publishing House Italy, 2013:74-160.

Published

2018-01-21

How to Cite

1.
Lotti T, Tchernev G, Wollina U, França K, Lotti J, Satolli F, Rovesti M, Gianfaldoni S. Successful Treatment with UVA 1 Laser of Non - Responder Vitiligo Patients. Open Access Maced J Med Sci [Internet]. 2018 Jan. 21 [cited 2021 Apr. 12];6(1):43-5. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2018.047

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>